Please use this identifier to cite or link to this item:
|Title:||Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: A Cancer Therapeutics Research Group study||Authors:||Soo, R.A.
|Keywords:||Fixed dose rate
Non-small-cell lung cancer
Phase I study
|Issue Date:||1-Aug-2003||Citation:||Soo, R.A., Lim, H.L., Wang, L.Z., Lee, H.S., Millward, M.J., Tok, L.T., Lee, S.C., Lehnert, M., Goh, B.C. (2003-08-01). Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: A Cancer Therapeutics Research Group study. Cancer Chemotherapy and Pharmacology 52 (2) : 153-158. ScholarBank@NUS Repository. https://doi.org/10.1007/s00280-003-0637-5||Abstract:||Purpose: To determine the maximally tolerated dose (MTD) of gemcitabine administered at a fixed dose-rate of 10 mg/m2 per min in combination with fixed dose carboplatin, to evaluate the toxicity of this regimen and to determine the pharmacokinetics of plasma gemcitabine. Methods: Patients with advanced stage non-small-cell lung cancer (NSCLC) received carboplatin (AUC 5) on day 1 followed by gemcitabine at a fixed dose rate of 10 mg/m2 per min in escalating durations of infusion on days 1 and 8 every 21 days. Pharmacokinetic sampling was obtained on day 1, cycle 1 of treatment. Results: A total of 15 patients received carboplatin and gemcitabine in cohorts of three to six patients at three dose levels. The doses of gemcitabine studied were 600, 750, and 900 mg/m2. The MTD was reached at 900 mg/m2. Dose-limiting toxicities were thrombocytopenia and liver failure, and with repeated dosing neutropenia was commonly observed. The recommended phase II dose of gemcitabine was 750 mg/m2. Partial responses were observed at 600 and 750 mg/m2 of gemcitabine. Plasma gemcitabine did not reach steady state except in one patient with the durations of infusion studied. Plasma concentrations, however, were above 10 μmol/l between 20 and 90 min in all patients. Conclusions: Gemcitabine administered as a 75-min infusion at a fixed dose rate of 10 mg/m2/min on days 1 and 8 in combination with carboplatin on day 1 every 21 days is tolerable and active in NSCLC. Pharmacokinetic studies demonstrated that the target plasma gemcitabine concentration above 10 μmol/l was achieved. Further studies are warranted to compare this regimen against standard regimens of carboplatin and gemcitabine.||Source Title:||Cancer Chemotherapy and Pharmacology||URI:||http://scholarbank.nus.edu.sg/handle/10635/106214||ISSN:||03445704||DOI:||10.1007/s00280-003-0637-5|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jul 31, 2020
WEB OF SCIENCETM
checked on Jul 31, 2020
checked on Aug 1, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.